Gilenya (fingolimod)

The first oral disease-modifying therapy approved for relapsing forms of MS. Gilenya changed the treatment landscape by giving patients a daily pill instead of injections or infusions.

Fingolimod works by mimicking a natural molecule called sphingosine-1-phosphate (S1P). It binds to S1P receptors on immune cells (lymphocytes) in lymph nodes and essentially traps them there. Since these immune cells can't leave the lymph nodes and travel to the brain and spinal cord, they can't cause the inflammation and nerve damage that drives MS relapses.

Requires first-dose monitoring (6 hours) due to risk of slowed heart rate (bradycardia). Other risks include macular edema (eye swelling), liver enzyme elevations, increased blood pressure, and increased risk of infections including progressive multifocal leukoencephalopathy (PML). Regular eye exams and blood tests are required. Infections can be serious or even fatal, including herpes and cryptococcal (fungal) infections. It may harm an unborn baby, so women who could become pregnant should use effective birth control during treatment and for 2 months after stopping. It raises the risk of skin cancers, so skin checks are advised before or soon after starting and regularly after that, and lymphoma has also been reported. The label also warns about a rare brain swelling condition called PRES, reduced lung function, severe relapses with large brain lesions (tumefactive MS), and allergic reactions.

Approved for relapsing forms of MS in people 10 years and older. Taken as one 0.5 mg capsule by mouth once daily; children 10 and older who weigh 40 kg or less take 0.25 mg once daily. First dose must be given in a healthcare setting with heart rate monitoring for at least 6 hours. The FDA approved the first generics in December 2019, and they reached US pharmacies in 2022 after a patent dispute ended.

Yes, Fingolimod (Gilenya) is FDA approved (2010) for the treatment of Multiple Sclerosis.

Fingolimod can temporarily slow the heart rate (bradycardia) when first taken, because S1P receptors are present on heart cells. The heart rate starts to drop within an hour of the first dose, usually reaches its lowest point within 6 hours, and mostly recovers by 8 to 10 hours. A second, sometimes larger dip can happen within 24 hours. Patients must be monitored in a healthcare setting for at least 6 hours after the first dose, with heart rate and blood pressure checks every hour. After the first dose, the heart adapts and the effect diminishes with continued daily use.

Yes. The FDA approved the first generic fingolimod in December 2019, but generics did not launch in the US until 2022, after a court ruled Novartis's dosing patent invalid. Multiple generic manufacturers now produce 0.5 mg capsules, which has significantly reduced the cost compared to branded Gilenya. Generic versions contain the same active ingredient and must meet FDA bioequivalence standards. Patients switching to a generic should see no difference in efficacy.

Fingolimod was the first oral MS therapy (approved 2010) and remains effective, with about 50% reduction in relapse rate. Newer S1P modulators like ozanimod and siponimod offer improved receptor selectivity with potentially fewer cardiac side effects. However, fingolimod's long track record and generic availability make it a cost-effective option. Your neurologist can help weigh the trade-offs between newer agents and fingolimod's established safety profile and lower cost.

Stopping fingolimod can lead to a rebound increase in disease activity, with some patients experiencing severe relapses within weeks to months of discontinuation. This rebound effect occurs because lymphocytes that were trapped in lymph nodes are rapidly released back into circulation. If you need to stop fingolimod, your neurologist should plan a transition strategy, often starting another disease-modifying therapy promptly to reduce the risk of rebound.

Yes. Macular edema (swelling in the center of the retina) occurred in about 0.5% of adults taking fingolimod 0.5 mg in 2-year trials. Symptoms can include blurred or distorted vision. An eye exam is recommended before or near the start of treatment, again 3-4 months after starting, periodically thereafter, and any time vision changes. Patients with diabetes or a history of uveitis are at higher risk. Macular edema usually resolves after stopping the drug, but early detection through regular eye exams is important.

Yes. Because fingolimod keeps lymphocytes sequestered in lymph nodes, it reduces the circulating immune cell count and increases susceptibility to infections. The most concerning rare infection is progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. More common infections include herpes virus reactivation, respiratory infections, and skin infections. Your neurologist will monitor your lymphocyte counts regularly and may check JC virus antibody status.